Last reviewed · How we verify
Stero Biotechs Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| CBD | CBD | marketed | Cannabinoid | 5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric) | Neurology, Psychiatry, Pain Management, Immunology |
Therapeutic area mix
- Neurology, Psychiatry, Pain Management, Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Gold Coast Hospital and Health Service · 1 shared drug class
- Hôpital le Vinatier · 1 shared drug class
- Montefiore Medical Center · 1 shared drug class
- OMNI Medical Services, LLC · 1 shared drug class
- Staci Gruber, Ph.D. · 1 shared drug class
- University of California, San Diego · 1 shared drug class
- University of Connecticut · 1 shared drug class
- Wayne State University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Stero Biotechs Ltd.:
- Stero Biotechs Ltd. pipeline updates — RSS
- Stero Biotechs Ltd. pipeline updates — Atom
- Stero Biotechs Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Stero Biotechs Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stero-biotechs-ltd. Accessed 2026-05-16.